Ocugen Inc (OCGN)

$0.71 -0.09 (-11.66%)
Market Cap 233.47M
Revenue (ttm) 4.06M
Net Income (ttm) -54.05M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,331.28%
Debt to Equity Ratio 0.97
Volume 5,313,100
Avg Vol 3,883,608
Day's Range N/A - N/A
Shares Out 292.01M
Stochastic %K 100%
Beta 3.88
Analysts Strong Sell
Price Target $6.75

Latest News on OCGN

Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema

Mar 18, 2025, 8:02 AM EDT - 13 days ago

Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema

Ocugen, Inc. (OCGN) Q4 2024 Earnings Call Transcript

Mar 5, 2025, 10:59 AM EST - 26 days ago

Ocugen, Inc. (OCGN) Q4 2024 Earnings Call Transcript

Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results

Mar 5, 2025, 7:02 AM EST - 26 days ago

Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results

Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease

Feb 27, 2025, 8:46 AM EST - 4 weeks ago

Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease

Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Feb 21, 2025, 8:00 AM EST - 5 weeks ago

Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Feb 12, 2025, 7:42 AM EST - 6 weeks ago

Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Ocugen Announces Positive Opinion of European Medicines Agency's Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa

Feb 3, 2025, 6:30 AM EST - 2 months ago

Ocugen Announces Positive Opinion of European Medicines Agency's Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa

Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19

Jan 27, 2025, 6:30 AM EST - 2 months ago

Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19

Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema

Jan 16, 2025, 7:30 AM EST - 2 months ago

Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema

Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 —A Novel Modifier Gene Therapy for Retinitis Pigmentosa

Jan 13, 2025, 6:30 AM EST - 2 months ago

Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 —A Novel Modifier Gene Therapy for Retinitis Pigmentosa

Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Dec 19, 2024, 6:38 AM EST - 3 months ago

Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit

Dec 11, 2024, 7:02 AM EST - 3 months ago

Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit

Ocugen CEO to Present at NobleCon20 – Noble Capital Markets' 20th Annual Emerging Growth Equity Conference

Nov 27, 2024, 7:09 AM EST - 4 months ago

Ocugen CEO to Present at NobleCon20 – Noble Capital Markets' 20th Annual Emerging Growth Equity Conference

Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease

Nov 20, 2024, 7:30 AM EST - 4 months ago

Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease

Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Nov 19, 2024, 7:02 AM EST - 4 months ago

Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Ocugen, Inc. (OCGN) Q3 2024 Earnings Call Transcript

Nov 8, 2024, 10:18 AM EST - 5 months ago

Ocugen, Inc. (OCGN) Q3 2024 Earnings Call Transcript

Ocugen Provides Business Update with Third Quarter 2024 Financial Results

Nov 8, 2024, 6:45 AM EST - 5 months ago

Ocugen Provides Business Update with Third Quarter 2024 Financial Results

Ocugen Secures $30 Million in Debt Funding

Nov 7, 2024, 6:30 AM EST - 5 months ago

Ocugen Secures $30 Million in Debt Funding

Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024

Oct 28, 2024, 6:30 AM EDT - 5 months ago

Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024

Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease

Oct 22, 2024, 7:02 AM EDT - 5 months ago

Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease

Ocugen to Host Conference Call on Friday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2024 Financial Results

Oct 17, 2024, 7:30 AM EDT - 5 months ago

Ocugen to Host Conference Call on Friday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2024 Financial Results

Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for OCU200 Phase 1 Clinical Trial

Oct 9, 2024, 6:30 AM EDT - 6 months ago

Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for OCU200 Phase 1 Clinical Trial

Ocugen to Present at the 2024 Cell & Gene Meeting on the Mesa

Oct 2, 2024, 6:30 AM EDT - 6 months ago

Ocugen to Present at the 2024 Cell & Gene Meeting on the Mesa

Ocugen to Participate in a Fireside Chat at Chardan's 8th Annual Genetic Medicines Conference

Sep 24, 2024, 7:30 AM EDT - 6 months ago

Ocugen to Participate in a Fireside Chat at Chardan's 8th Annual Genetic Medicines Conference

Kaskela Law LLC Announces Shareholder Investigation of Ocugen, Inc. (NASDAQ: OCGN) and Encourages Investors to Contact the Firm

Sep 17, 2024, 8:00 AM EDT - 6 months ago

Kaskela Law LLC Announces Shareholder Investigation of Ocugen, Inc. (NASDAQ: OCGN) and Encourages Investors to Contact the Firm

Ocugen Extends Cash Runway As OCU400 Nears Key Milestones In Phase 3

Sep 17, 2024, 2:25 AM EDT - 6 months ago

Ocugen Extends Cash Runway As OCU400 Nears Key Milestones In Phase 3

Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop

Sep 9, 2024, 6:30 AM EDT - 7 months ago

Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop

Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit

Sep 5, 2024, 7:00 AM EDT - 7 months ago

Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit

Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 7:30 AM EDT - 7 months ago

Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference

Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy

Aug 28, 2024, 6:30 AM EDT - 7 months ago

Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy

Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication

Aug 26, 2024, 7:02 AM EDT - 7 months ago

Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication

Ocugen, Inc. Investor Alert (NASDAQ: OCGN): Schubert Jonckheer & Kolbe LLP Investigating Potential Claims Against the Company's Officers and Directors Following Earnings Restatement and Possible Insider Trading

Aug 20, 2024, 9:00 AM EDT - 7 months ago

Ocugen, Inc. Investor Alert (NASDAQ: OCGN): Schubert Jonckheer & Kolbe LLP Investigating Potential Claims Against the Company's Officers and Directors Following Earnings Restatement and Possible Insider Trading

Ocugen Provides Business Update with Second Quarter 2024 Financial Results

Aug 8, 2024, 6:45 AM EDT - 8 months ago

Ocugen Provides Business Update with Second Quarter 2024 Financial Results

Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa

Aug 5, 2024, 6:30 AM EDT - 8 months ago

Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa

Ocugen, Inc. Announces Closing of $35 Million Public Offering of Common Stock

Aug 2, 2024, 3:22 PM EDT - 8 months ago

Ocugen, Inc. Announces Closing of $35 Million Public Offering of Common Stock

Ocugen, Inc. Announces Pricing of $35 Million Public Offering of Common Stock

Jul 31, 2024, 9:15 PM EDT - 8 months ago

Ocugen, Inc. Announces Pricing of $35 Million Public Offering of Common Stock

Ocugen, Inc. Announces Proposed Public Offering of Common Stock

Jul 31, 2024, 4:15 PM EDT - 8 months ago

Ocugen, Inc. Announces Proposed Public Offering of Common Stock

Ocugen to Host Conference Call on Thursday, August 8 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2024 Financial Results

Jul 29, 2024, 7:02 AM EDT - 8 months ago

Ocugen to Host Conference Call on Thursday, August 8 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2024 Financial Results

Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Novel Modifier Gene Therapy

Jul 25, 2024, 6:30 AM EDT - 8 months ago

Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Novel Modifier Gene Therapy

Ocugen: Paradigm Shift Gene Therapy Facing Cash Flow Hurdles

Jul 1, 2024, 11:07 AM EDT - 9 months ago

Ocugen: Paradigm Shift Gene Therapy Facing Cash Flow Hurdles

Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease

Jun 21, 2024, 7:00 AM EDT - 10 months ago

Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease

Ocugen, Inc. Announces First Patient Dosed in Phase 3 liMeliGhT Clinical Trial for OCU400—First Gene Therapy in Phase 3 with a Broad Retinitis Pigmentosa Indication

Jun 20, 2024, 6:30 AM EDT - 10 months ago

Ocugen, Inc. Announces First Patient Dosed in Phase 3 liMeliGhT Clinical Trial for OCU400—First Gene Therapy in Phase 3 with a Broad Retinitis Pigmentosa Indication

DEADLINE TODAY: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm

Jun 10, 2024, 10:20 AM EDT - 10 months ago

DEADLINE TODAY: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm

The Schall Law Firm Encourages Investors With Losses in Ocugen, Inc. to Touch Base With the Firm Before the June 10th Deadline

Jun 9, 2024, 11:00 AM EDT - 10 months ago

The Schall Law Firm Encourages Investors With Losses in Ocugen, Inc. to Touch Base With the Firm Before the June 10th Deadline

Reminder for the June 10th Deadline: The Schall Law Firm Encourages Investors With Losses in Ocugen, Inc. to Reach Out

Jun 7, 2024, 11:00 AM EDT - 10 months ago

Reminder for the June 10th Deadline: The Schall Law Firm Encourages Investors With Losses in Ocugen, Inc. to Reach Out

June 10th Deadline Reminder: The Schall Law Firm Invites Ocugen, Inc. Investors With Losses To Connect

Jun 6, 2024, 11:00 AM EDT - 10 months ago

June 10th Deadline Reminder: The Schall Law Firm Invites Ocugen, Inc. Investors With Losses To Connect

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen

Jun 5, 2024, 10:40 AM EDT - 10 months ago

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen

FINAL DEADLINE NEXT WEEK: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses In Excess of $250,000 to Contact the Firm

Jun 4, 2024, 11:45 AM EDT - 10 months ago

FINAL DEADLINE NEXT WEEK: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses In Excess of $250,000 to Contact the Firm

OCGN DEADLINE ACTION REMINDER: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm

Jun 4, 2024, 11:00 AM EDT - 10 months ago

OCGN DEADLINE ACTION REMINDER: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm